Table 3.

Three year follow up study of patients (n = 182) suffering from rheumatoid arthritis (RA) and treated with RA-1 (standard Ayurvedic formulation) following 16 week randomization phase: Use of RA-1, low dose steroids and DMARD. Shows proportion of patients (percent).

Drug/evaluation end points (weeks)	Any post week 16	0–16	16–52	52–104	104–156
RA-1 Only	38.2	58.2	46.4	52.4	47.5
DMARD	35.8	0	21.2	19.9	33.6
Steroids	55.5	41.8	45.5	41.8	45.9
Any DMARD or steroid	61.8	41.8	54.6	48.6	52.5
Chloroquine	18.8	Nil	7.9	6	13.8
Methotrexate	19.6	Nil	11.9	16.2	18.8

All patients received background treatment with RA-1; n: number of patients; 0 and week 16 pertain to randomization phase; low dose steroid pertain to equal or less than 7.5 mg daily prednisolone; DMARD include chloroquine sulfate, methotrexate and sulfasalazine; see text for details.